

# Peter Yu-wei Chang, MD, FACS

## PROFESSIONAL

### **Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, MA**

- Co-President and Owner
- Laboratory Director
- Diplomate, American Board of Ophthalmology
- Fellow, American College of Surgeons
- Clinical interests: Uveitis, ocular inflammatory disease, vitreoretinal surgery, complex cataract
- Hospital affiliations and privileges:

Massachusetts General Hospital (Boston, MA)	2/2024 – Present
Massachusetts Eye and Ear Infirmary (Boston, MA)	7/2016 – Present
Mount Auburn Hospital (Cambridge, MA)	12/2016 – Present
Newton-Wellesley Hospital (Newton, MA)	2/2018 – Present
Beth Israel Deaconess Hospital – Needham (Needham, MA)	3/2018 – Present
UMass Memorial Medical Center (Worcester, MA)	2/2020 – Present

### **Ocular Immunology and Uveitis Foundation (OIUF), Weston, MA**

- Board of Trustees
- Research Committee

### **Specialty Eye Consultants (SEC), Reading, MA**

- Co-Owner

## EDUCATION

### **Tufts University School of Medicine**

8/2004 – 5/2008

- Doctor of Medicine

**Brown University** 9/2000 – 5/2004

- Bachelor of Science in Biology

### **POSTGRADUATE TRAINING**

**Illinois Eye and Ear Infirmary** 7/2014 – 7/2016

- Fellow, Vitreoretinal Surgery

**New York Eye and Ear Infirmary** 7/2011 – 6/2014

- Resident, Ophthalmology
- Chief Administrative Resident (2013 – 2014)

**Mount Auburn Hospital** 6/2010 – 6/2011

- Intern, Internal Medicine
- Clinical Instructor, Harvard Medical School

**Massachusetts Eye Research and Surgery Institution** 6/2008 – 6/2010

- Chief Research Fellow, Uveitis and Ocular Immunology
- Associate, Ocular Immunology and Uveitis Foundation
- Assistant Editor, *Contemporary Ophthalmology*

### **AWARDS**

1. Newsweek America's Best 200 Ophthalmologists (2023)
2. Boston Magazine Top Doctors (2022 - present)
3. Castle Connolly Top Doctors (2021 - present)
4. Fellow of the Year (Red Apple Award), Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago/Illinois Eye and Ear Infirmary (2015)
5. Chief Resident Recognition Award, New York Eye and Ear Infirmary of Mount Sinai (2014)
6. Immunology Award. Massachusetts Eye Research and Surgery Institution (2011)
7. Special Recognition Award, Volunteer Department, Massachusetts General Hospital (2003)

## CLINICAL TRIALS

1. Study of Xiflam™ Treatment in Patients Post COVID-19 Infection Suffering From What is Known as Long COVID (NCT06437223)
  - Sponsor: Inflammx Therapeutics
  - Single-site
  - Principal Investigator
  - 3/2024 – 3/2025 (projected)
  
2. Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study (NCT06085079)
  - Sponsor: Eli Lilly
  - Single-site (investigator-initiated)
  - Principal investigator
  - 6/2022 – 2/2024
  
3. Phase 4 Study of YUTIQ (Fluocinolone Acetonide Intravitreal Implant) 0.18mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis Study (SYNCHRONICITY, NCT05322070)
  - Sponsor: Alimera Sciences
  - Multicenter
  - Principal Investigator
  - 6/2022 – 11/2025 (projected)
  
4. Real-World Data on YUTIQ, a Fluocinolone Acetonide Intravitreal Implant, for the Treatment of Chronic Non-infectious Uveitis Affecting the Posterior Segment (CALM REGISTRY)
  - Sponsor: Alimera Sciences
  - Multicenter
  - Principal Investigator
  - Ongoing data collection

5. A Phase 2b-pivotal study to evaluate the efficacy and safety of Izokibep in subjects with non-infectious, intermediate, posterior- or pan-uveitis (NCT05384249)
  - Sponsor: Acelyrin
  - Multicenter
  - Principal investigator
  - 8/2022 – 10/2024 (projected)
  
6. Descares-8 (Autologous T-cells expressing a chimeric antigen receptor directed to B-cell maturation antigen) for autoimmune ocular inflammatory disease
  - Sponsor: Cartesian Therapeutics
  - Investigator-initiated, single-site
  - Principal Investigator
  - 4/2023 – 12/2023
  
7. A Phase 2 Randomized, Double-Masked, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Active Non-Infectious Intermediate-, Posterior-, and Panuveitis (NEPTUNE, NCT05523765)
  - Sponsor: Priovant
  - Multicenter
  - Sub-PI
  - 11/2022 – 7/2023
  
8. Proof-of-concept Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU (OPTYK-1, NCT05953688)
  - Sponsor: Alumis
  - Multicenter
  - Sub-PI
  - 6/2023 – 4/2025 (projected)

9. A Phase 3 randomized, Active- Controlled, Double-Masked Study to Evaluate the Safety and Efficacy of TRS01 Eye Drops in the treatment of Subjects with Active Non-infectious Anterior Uveitis including Subjects with Uveitis Glaucoma (NCT05042609)
  - Sponsor: Tarsier Pharma
  - Multicenter
  - Sub-PI
  - 9/2021 – 6/2023
  
10. Multi-centered, randomized (1:1) study, with Single- Masked, Run-In vehicle Treatment Phase Study to Evaluate the Safety and Efficacy of Tivanisiran Sodium Ophthalmic Solution (1.125%) in Treating DED Signs and Symptoms in Subjects With a Documented Diagnosis of Dry Eye Associated with Sjogren’s Syndrome (NCT04819269)
  - Sponsor: Sylentis
  - Multicenter
  - Sub-PI
  - 5/2021 – 12/2023

### **PUBMED-INDEXED PUBLICATIONS**

1. Rujkorakarn P, Zhou A, Babiker F, **Chang PY**. Suprachoroidal triamcinolone injection in posterior scleritis: a case report. *Ocul Immunol Inflamm.* 2023 Jul 14:1-4.
  
2. Zhou Y, Zhou A, Philip AM, Margolis M, Babiker F, **Chang PY**, Anesi SD, Foster CS. Vision Outcomes of Long-Term Immunomodulatory and Steroid Therapy in Sympathetic Ophthalmia. *Am J Ophthalmol.* 2023 Sep;253:152-159. doi: 10.1016/j.ajo.2023.05.004. Epub 2023 May 5. PMID: 37150338.
  
3. Philip AM, Anesi SD, Foster CS, **Chang P**. Ocular Inflammatory Complications of Treatment for Metastatic Melanoma. *Ocul Immunol Inflamm.* 2023 Oct;31(8):1669-1673. doi: 10.1080/09273948.2022.2098147. Epub 2022 Aug 1. PMID: 35914291.
  
4. Maleki A, Fernandez CC, Philip AM, Manhapa A, **Chang PY**, Foster CS. Acute macular neuroretinopathy in a patient with birdshot chorioretinopathy after intravitreal triamcinolone

suspension injection. *Eur J Ophthalmol*. 2023 Sep;33(5):NP35-NP40. doi: 10.1177/11206721221124653. Epub 2022 Sep 4. PMID: 36062613.

5. Maleki A, Look-Why S, Manhapra A, Asgari S, Garcia CM, Al-Dabbagh A, Tsang C, **Chang PY**, Anesi SD, Foster CS. Birdshot Chorioretinopathy: Resistant versus Responsive. *Ocul Immunol Inflamm*. 2023 Apr;31(3):477-482. doi: 10.1080/09273948.2022.2032193. Epub 2022 Mar 30. PMID: 35353656.
6. Anesi SD, **Chang PY**, Maleki A, Manhapra A, Look-Why S, Asgari S, Walsh M, Drenen K, Foster CS. Effects of Subcutaneous Repository Corticotropin Gel Injection on Regulatory T Cell Population in Noninfectious Retinal Vasculitis. *Ocul Immunol Inflamm*. 2023 Apr;31(3):556-565. doi: 10.1080/09273948.2022.2042323. Epub 2022 Mar 8. PMID: 35258389.
7. Maleki A, Look-Why S, Manhapra A, Asgari S, Philip AM, **Chang PY**, Anesi SD, Foster CS. Late recurrence in birdshot chorioretinopathy. *Can J Ophthalmol*. 2023 Apr;58(2):77-81. doi: 10.1016/j.jcjo.2021.08.006. Epub 2021 Sep 14. PMID: 34534507.
8. Philip AM, Fernandez-Santos CC, Ramezani K, Dolinko AH, Manhapra A, Look-Why S, **Chang PY**, Foster CS, Anesi SD. Ocular Mucus Membrane Pemphigoid: A Primary Versus Secondary Entity. *Cornea*. 2023 Mar 1;42(3):280-283. doi: 10.1097/ICO.0000000000003056. Epub 2022 Aug 24. PMID: 36036657.
9. Anesi SD, Tauber J, Nguyen QD, **Chang P**, Berdy GJ, Lin CC, Chu DS, Levine HT, Fernandez AD, Roy N, Asbell PA, Kantor AM, Chang AT, Singh B, Youngblood BA, Jeng BH, Jhanji V, Rasmussen HS, Foster CS. Lirentelimab for severe and chronic forms of allergic conjunctivitis. *J Allergy Clin Immunol*. 2022 Sep;150(3):631-639. doi: 10.1016/j.jaci.2022.03.021. Epub 2022 Apr 4. PMID: 35390403.
10. Lin M, Anesi SD, **Chang PY**, Eggenschwiler L, Manhapra A, Walsh M, Foster CS. Clinical features, visual outcome, and poor prognostic factors in occlusive retinal vasculitis. *Can J Ophthalmol*. 2022 Jun;57(3):207-213. doi: 10.1016/j.jcjo.2021.03.001. Epub 2021 Apr 7. PMID: 33838140.
11. Tripathy K, Ying H, Maldonado Cerda A, Filipowicz A, Kaya M, Seymen Z, Anesi SD, **Chang PY**, Foster CS. Widefield Fundus Fluorescein Angiography Features of Uveitis Associated with Juvenile Idiopathic Arthritis. *Ocul Immunol Inflamm*. 2022 May 19;30(4):829-838. doi: 10.1080/09273948.2020.1834586. Epub 2020 Dec 2. PMID: 33264037.

12. Maleki A, Ueberroth JA, Manhapra A, Walsh M, Asgari S, **Chang PY**, Anesi SD, Foster CS. Fixed-Luminance and Multi-Luminance Flicker Electroretinography Parameters in Patients with Early Active Birdshot Chorioretinopathy. *Ocul Immunol Inflamm.* 2022 Jan 2;30(1):129-135. doi: 10.1080/09273948.2020.1797113. Epub 2020 Aug 20. PMID: 32816569.
13. Maleki A, Ueberroth JA, Walsh M, Foster F, **Chang PY**, Anesi SD, Foster CS. Combination of Intravenous Methotrexate and Methylprednisolone Therapy in the Treatment of Severe Ocular Inflammatory Diseases. *Ocul Immunol Inflamm.* 2021 Nov 17;29(7-8):1559-1563. doi: 10.1080/09273948.2020.1746356. Epub 2020 May 14. PMID: 32406782.
14. Filipowicz A, Coca MN, Blair BM, **Chang PY**. Acute Myocarditis with Cardiogenic Shock and Multiple Organ Failure, Followed by Bilateral Panuveitis Masquerading as Endogenous Endophthalmitis, Due to *Toxoplasma Gondii* in an Immunocompetent Patient. *Retin Cases Brief Rep.* 2021 Sep 1;15(5):575-580. doi: 10.1097/ICB.0000000000000855. PMID: 30664080.
15. Zhu I, Haq Z, Ali MH, **Chang PY**, Zahid S, Mieler WF. Application of Adjunctive Topical Mitomycin-c in Sclerostomy Revision for Refractory Idiopathic Uveal Effusion Syndrome. *Retin Cases Brief Rep.* 2021 Jul 1;15(4):339-343. doi: 10.1097/ICB.0000000000000840. PMID: 30614924.
16. Anesi SD, **Chang PY**, Maleki A, Stephenson A, Montieth A, Filipowicz A, Syeda S, Asgari S, Walsh M, Metzinger JL, Foster CS. Treatment of Noninfectious Retinal Vasculitis Using Subcutaneous Repository Corticotropin Injection. *J Ophthalmic Vis Res.* 2021 Apr 29;16(2):219-233. doi: 10.18502/jovr.v16i2.9086. PMID: 34055260; PMCID: PMC8126741.
17. Maleki A, Manhapra A, Asgari S, **Chang PY**, Foster CS, Anesi SD. Tocilizumab Employment in the Treatment of Resistant Juvenile Idiopathic Arthritis Associated Uveitis. *Ocul Immunol Inflamm.* 2021 Jan 2;29(1):14-20. doi: 10.1080/09273948.2020.1817501. Epub 2020 Oct 6. PMID: 33021415.
18. **Chang PY**, Klemencic SA, Ulanski LJ. Intraocular Tumor Associated With Visual Loss in a Young Woman. *JAMA Ophthalmol.* 2016 Jul 1;134(7):833-4. doi: 10.1001/jamaophthalmol.2015.5341. PMID: 27258118.
19. Bojikian KD, Gupta D, Dettori JM, Dettori NJ, Dettori JR, **Chang P**, Slabaugh MA. Evidence in Ophthalmology: Are We Doing Better? *Ophthalmology.* 2015 Dec;122(12):2584-6. doi: 10.1016/j.ophtha.2015.06.012. Epub 2015 Aug 4. PMID: 26253371.

20. Kord Valeshabad A, Francis AW, Setlur V, **Chang P**, Mieler WF, Shahidi M. Hemorrhagic Retinopathy after Spondylosis Surgery and Seizure. *Optom Vis Sci*. 2015 Aug;92(8):e190-3. doi: 10.1097/OPX.0000000000000637. PMID: 26099062; PMCID: PMC4515162.
21. **Chang PY**, Kresch Z, Samson CM, Gentile RC. Spontaneous Dissociation of Fluocinolone Acetonide Sustained Release Implant (Retisert) with Dislocation into the Anterior Chamber. *Ocul Immunol Inflamm*. 2015;23(6):454-7. doi: 10.3109/09273948.2014.902074. Epub 2015 Aug 27. PMID: 24724735.
22. Lerman MA, Burnham JM, **Chang PY**, Daniel E, Foster CS, Hennessy S, Jabs DA, Joffe MM, Kaçmaz RO, Levy-Clarke GA, Mills MD, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Kempen JH. Response of pediatric uveitis to tumor necrosis factor- $\alpha$  inhibitors. *J Rheumatol*. 2013 Aug;40(8):1394-403. doi: 10.3899/jrheum.121180. Epub 2013 Jul 1. PMID: 23818712; PMCID: PMC3802519.
23. Giuliari GP, **Chang PY**, Muci-Mendoza R, Cortez RT. A case of acute multifocal inner retinitis associated with nonspecific viral illness. *Retin Cases Brief Rep*. 2012 Winter;6(1):40-2. doi: 10.1097/ICB.0b013e3182051d06. PMID: 25390708.
24. **Chang PY**, Hamam R, Giuliari GP, Foster CS. Cytomegalovirus panuveitis associated with papillitis in an immunocompetent patient. *Can J Ophthalmol*. 2012 Aug;47(4):e12-3. doi: 10.1016/j.jejo.2012.03.011. Epub 2012 Jun 29. PMID: 22883854.
25. Turkcuoglu P, **Chang PY**, Rentiya ZS, Channa R, Ibrahim M, Hatfe E, Sophie R, Sadaka A, Wang J, Sepah YJ, Do DV, Foster CS, Nguyen QD. Mycophenolate mofetil and fundus autofluorescence in the management of recurrent punctate inner choroidopathy. *Ocul Immunol Inflamm*. 2011 Aug;19(4):286-92. doi: 10.3109/09273948.2011.580072. PMID: 21770809.
26. Giuliari GP, Sadaka A, **Chang PY**, Cortez RT. Diabetic papillopathy: current and new treatment options. *Curr Diabetes Rev*. 2011 May;7(3):171-5. doi: 10.2174/157339911795843122. PMID: 21418004.
27. **Chang PY**, Giuliari GP, Shaikh M, Thakuria P, Makhoul D, Foster CS. Mycophenolate mofetil monotherapy in the management of paediatric uveitis. *Eye (Lond)*. 2011 Apr;25(4):427-35. doi: 10.1038/eye.2011.23. Epub 2011 Mar 18. PMID: 21423146; PMCID: PMC3171236.
28. Siddique SS, Gonzalez-Gonzalez LA, Thakuria P, **Chang PY**, Foster CS. Scleral necrosis in a patient with congenital erythropoietic porphyria. *Cornea*. 2011 Jan;30(1):97-9. doi: 10.1097/ICO.0b013e3181e458fa. PMID: 20847674.



29. Foster CS, **Chang PY**, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. *Ophthalmology*. 2010 May;117(5):861-9. doi: 10.1016/j.ophtha.2009.09.049. Epub 2010 Jan 4. PMID: 20045562.
30. Giuliari GP, **Chang PY**, Thakuria P, Hinkle DM, Foster CS. Pars plana vitrectomy in the management of paediatric uveitis: the Massachusetts Eye Research and Surgery Institution experience. *Eye (Lond)*. 2010 Jan;24(1):7-13. doi: 10.1038/eye.2009.294. Epub 2010 Jan 8. Erratum in: *Eye (Lond)*. 2010 May;24(5):946. PMID: 20057512.
31. Zakka FR, **Chang PY**, Giuliari GP, Foster CS. Current trends in the management of ocular symptoms in Adamantiades-Behçet's disease. *Clin Ophthalmol*. 2009;3:567-79. doi: 10.2147/opth.s4445. Epub 2009 Oct 19. PMID: 19898629; PMCID: PMC2770868.
32. Williams L, **Chang PY**, Park E, Gorson KC, Bayer-Zwirello L. Successful treatment of dermatomyositis during pregnancy with intravenous immunoglobulin monotherapy. *Obstet Gynecol*. 2007 Feb;109(2 Pt2):561-3. doi: 10.1097/01.AOG.0000253244.45837.7c. PMID: 17267895.

### MISCELLANEOUS PUBLICATIONS

1. **Chang PY**. Case reports: use of fluocinolone acetonide intravitreal implant to manage chronic panuveitis for long-term inflammatory control without interfering with systemic immunity. *Digit J Ophthalmol*. Published online December 28, 2022. doi:10.5693/djo.02.2022.10.002
2. Anesi SD, **Chang PY**. Controlling flares in chronic noninfectious uveitis. *Retina Today* May/June 2020.
3. **Chang PY**, Bradbury MJ. Age-related macular degeneration: current status and treatment. *Worcester Medicine* March/April 2019.
4. **Chang PY**, Leiderman YI. Optimizing surgery for the luxated lens: torsional phaco pars plana vitrectomy. *Retina Today* October 2014.
5. Hoguet A, Sullivan T, Rosenberg K, **Chang PY**, Sidoti PA. Review of “Using multiple trabecular micro-bypass stents in cataract patients to treat open-angle glaucoma.” *EyeWorld* November 2012;72-3.
6. **Chang PY**, Siddique SS, Shaikh M, Foster CS. Topical corticosteroids in ocular diseases. *Current Topics in Steroid Research* 2010;7:1-10.
7. Giuliari GP, **Chang PY**, Cortez RT. Rhegmatogenous retinal detachment: general concepts and treatment options. *Contemporary Ophthalmology* 2010; 9(12): 1-8.

8. **Chang PY**, Foster CS. Stopping the progression of uveitic glaucoma: the MERSI experience. Uveitis (Journal of the Uveitis Information Group; Chief Editor: Manfred Zierhut, MD) 2009 edition: Uveitis and Glaucoma.
9. **Chang PY**, Foster CS, Hochberg FH. Primary CNS Lymphoma with Intraocular Involvement (short review of: Grimm SA et al. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology 2008;71:1355-60). Journal Watch Neurology 2009; 11(3): 21-2.
10. Doan S, **Chang PY**, Hoang-Xuan T. Conjunctival and lid inflammation in children. Contemporary Ophthalmology 2009; 8(2): 1-8.

### **BOOKS**

1. Chang PY, Foster CS. Toxoplasmosis. Albert and Jakobiec's Principles and Practices of Ophthalmology (4<sup>th</sup> ed). Springer, 2022.
2. Foster CS, Anesi SD, Chang PY, eds. Uveitis: A Quick Guide to Essential Diagnosis. Springer, 2021.
3. Chang PY, Foster CS. Necrotizing scleritis. In: Kaplan, Sandhu, eds. Clinical Cases in Uveitis: Differential Diagnosis and Management (1<sup>st</sup> ed). Elsevier, 2021.
4. Chang PY, Foster CS. Lyme intermediate uveitis. In: Kaplan, Sandhu, eds. Clinical Cases in Uveitis: Differential Diagnosis and Management (1<sup>st</sup> ed). Elsevier, 2021.
5. Anesi SD, Chang PY, Foster CS. Cicatrizing disorders of the ocular surface. In: Colby, Dana, eds. Foundations of Corneal Disease. Cham, Switzerland: Springer, 2020.
6. Giuliani GP, Chang PY. Pegaptanib sodium in the treatment of ocular vascular diseases: expectations and realities. In: Atta-ur-Rahman, Choudhary, eds. Frontiers in Drug Design & Discovery (Vol 5). Oak Park, IL: Bentham Science Publishers Ltd, 2010.
7. Contributor. In: Foster, Bhat, Yilmaz, Cervante, Mauro, eds. Atlas of Ocular Inflammatory Diseases (2<sup>nd</sup> edition)

### **LECTURES**

1. Sonoma Eye Meeting (March 2024)
  - a. Macular pucker in uveitis patients
  - b. CALM: 24-month data from a registry of patients with chronic NIU-PS treated with the 0.18mg fluocinolone acetonide intravitreal implant
2. International Pemphigus & Pemphigoid Foundation Patient Ed Conference (October 2023)
  - a. Ocular cicatricial pemphigoid: new treatment strategies
3. New England Ophthalmological Society (October 2023)

- a. Laboratory and imaging work-ups in uveitis
- 4. OIUF Ocular Inflammatory Diseases Crash Course, Scottsdale, AZ (September 2023)
  - a. Ocular complications of targeted oncologic therapy
  - b. Current uveitis trials
- 5. Nantucket Retina (July 2023)
  - a. Triamcinolone Acetonide Suprachoroidal Injection for Uveitic Macular Edema: Early Adopter Survey
- 6. Sonoma Eye Meeting (March 2023)
  - a. Neoplastic uveitis masquerade syndromes
  - b. Early adoption of triamcinolone acetonide suprachoroidal injection for uveitic macular edema: A physician survey
- 7. New England Ophthalmological Society (December 2022)
  - a. Suprachoroidal drug delivery
- 8. OIUF Ocular Inflammatory Diseases Crash Course, Miami, FL (November 2022)
  - a. Non-neoplastic uveitis masqueraders
  - b. Neoplastic uveitis masqueraders
  - c. Drug-induced uveitis and ocular complications of cancer immunotherapy
  - d. Diagnosis and management of vitreoretinal lymphoma
- 9. Downeast Symposium, Bar Harbor, ME (October 2022)
  - a. Uveitis masquerade syndromes
  - b. Ocular complications of cancer immunotherapy and drug-induced uveitis
  - c. Diagnosis and management of vitreoretinal lymphoma
- 10. Mass Eye & Ear Infirmery Resident Lecture Series (September 2022)
  - a. Medical therapy for non-infectious uveitis
- 11. New England Ophthalmological Society (December 2020)
  - a. Current treatment trends in ocular toxoplasmosis
- 12. 11<sup>th</sup> Annual Meeting, Ocular Immunology Division, Chinese Ophthalmological Society (September 2020)
  - a. YUTIQ (fluocinolone acetonide 0.18mg intravitreal implant): Clinical data and cases
- 13. New England Ophthalmological Society (April 2020)

- a. Moderator for session “Retinal Detachment: Diagnosis, Management, and Challenges”
14. New England Ophthalmological Society (November 2019)
    - a. Pars plana vitrectomy for the anterior segment surgeon
  15. New England Ophthalmological Society (May 2019)
    - a. Drug-induced uveitis
  16. Sonoma Eye Meeting (March 2019)
    - a. Moderator for session “Pediatric Uveitis”
    - b. Pars plana vitrectomy/endolaser/cryopexy for pars planitis: MERSI surgical outcomes
  17. Visiting Professor Lectures. New York Eye and Ear Infirmary (September 2018)
    - a. Uveitis review for the residents: Diagnostic approach and treatment
    - b. Birdshot retinochoroidopathy: Diagnosis, monitoring, and management
  18. Ocular Immunology and Uveitis Foundation Preventable Blindness Hot Topics Crash Course (April 2018)
    - a. Imaging tools that make a difference in ocular inflammatory disease
  19. EyeTech Continuing Education Conference (April 2018)
    - a. Diabetic retinopathy: Updates on diagnosis and treatment
  20. New England Ophthalmological Society (March 2018)
    - a. Treatment of recalcitrant ocular cicatricial pemphigoid with a combination therapy of rituximab and intravenous immunoglobulin
  21. Council on Optometric Practitioner Education Course (February 2018)
    - a. Macular surgery
  22. Ocular Immunology and Uveitis Foundation Symposium on Causes/Predictors of Uveitis (October 2017)
    - a. Differential diagnoses of childhood uveitis
  23. European Vitreoretinal Society (EVRS) 2017 Annual Meeting (September 2017)
    - a. Keynote Lecture: Birdshot retinochoroidopathy
    - b. Review of uveitis for retinal specialists
  24. Council on Optometric Practitioner Education Course (April 2017)
    - a. Retinal detachment and its management
  25. Carroll Center for the Blind Seminar (March 2017)

- a. Argus II retinal prosthesis
- 26. Ocular Immunology and Uveitis Foundation Posterior Segment Summit (November 2016)
  - a. What's new in diagnosis & treatment of diabetic retinopathy
  - b. Argus II retinal prosthesis
- 27. Council on Optometric Practitioner Education Course (October 2016)
  - a. Macular Degeneration
- 28. 27<sup>th</sup> Annual Midwest Ocular Angiography Conference (July 2015)
  - a. Idiopathic uveal effusion and its surgical management
  - b. Autoimmune versus tuberculous serpiginous choroidopathy
  - c. Sclerochoroidal calcification associated with hypomagnesemia
- 29. Chicago Rabb Retina Study Club
  - a. Massive submacular hemorrhage in neovascular age-related macular degeneration (September 2015)
  - b. Giant nodular posterior scleritis associated with exudative retinal detachment (December 2014)
- 30. 4<sup>th</sup> Annual MERSI Physician Education Conference (November 2009)
  - a. Retinal vascular occlusion: risk factor assessment and intervention therapy
- 31. 14<sup>th</sup> Annual Foster Ocular Immunology Society Meeting (May 2009)
  - a. Retinopathy associated with chronic myelogenous leukemia

## **EXTRACURRICULARS**

### **Professional Affiliations**

- American College of Surgeons
- American Society of Retina Specialists
- Foster Ocular Immunology Society
- American Academy of Ophthalmology
- Association for Research in Vision and Ophthalmology
- Massachusetts Medical Society
- Massachusetts Society of Eye Physicians and Surgeons
- New England Ophthalmological Society

- Mount Auburn Cambridge Independent Practice Association

**Scientific Advisory Board, Speaker Bureau, Consultancy**

- AbbVie
- Alcon
- Alimera Sciences
- Bausch & Lomb
- Biomere
- DORC (Dutch Ophthalmic Research Center)
- EyePoint Pharmaceuticals
- Genetech
- Mallinckrodt Pharmaceuticals
- Ocugen, Chair in Data Safety Monitoring Board (DSMB)
- Regeneron
- X4 Pharmaceuticals

**Teaching**

- |                                                                 |                |
|-----------------------------------------------------------------|----------------|
| • Lecturer, Massachusetts Eye and Ear Infirmary                 | 2022 – Present |
| • Instructor, Mount Auburn Hospital                             | 2017 – Present |
| • Lecturer, Council on Optometric Practitioner Education (COPE) | 2016 – 2019    |

**Journal Reviewer**

- American Journal of Ophthalmology
- Clinical Medicine Insights: Case Reports
- Journal of Vitreoretinal Diseases
- Retinal Cases and Brief Reports
- Survey of Ophthalmology

**Languages**

- English
- Chinese (Mandarin)